Romania Outlines Pharma Industry Development

2 April 1995

Romania's Ministry of Industries has reported that the country's pharmaceutical production this year will recover to its 1989 level, following five years of major decline, according to the Rompres news agency.

The national development program for the industry calls for major increases in both production and product quality over the next few years. Eventually, it is hoped that domestic drug production will account for 65% of total consumption, compared with 55% this year and 49% in 1994. The Ministry states optimistically that medicine quality and effectiveness will improve to make Romanian pharmaceuticals comparable to those manufactured abroad.

The Ministry's director general, Lucian Motiu, said that Romanian pharmaceuticals will compete with foreign products on the basis of their quality and affordability. Cooperation will be sought with foreign companies for the production in Romania under license of medicines in high demand on the Romanian market, he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight